Immunohistochemistry Neuroendocrine Tumor Panel in UAE | 1000 AED | DHA Licensed

Executive Summary & Core Metrics

Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing.
Specimen Logistics: Secure Medical Courier Solid Tissue Specimen Retrieval – Archival FFPE blocks accepted; mobile phlebotomy disabled.
Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Legal Compliance: This service strictly complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of ICT in Health Fields.

Test Overview & Methodology

The Immunohistochemistry Neuroendocrine Tumor Panel is a specialized pathology test that uses a panel of validated antibodies to characterize neuroendocrine neoplasms. It provides an immunophenotypic map including chromogranin A, synaptophysin, CD56, Ki-67, and hormonal markers, enabling precise tumor grading and therapeutic targeting.

Feature	Our Test (IHC Panel)	Closest Alternative
Precision	Multi-marker IHC with automated quantification & digital pathology	Single antibody testing, subjective scoring
Methodology	ISO 9001:2015 accredited IHC on FFPE tissue, full digital reporting	Standard manual IHC, limited QC
Turnaround Time	5–7 days from tissue receipt; rapid processing available	7–14 days, variable

Physician Insight & Safety Protocols

Mr. Prabhakar Reddy Kalathoor (Specialist Diagnostic Radiology, DHA ID: 61713011) emphasizes: “Every neuroendocrine tumor is biologically unique; IHC panels must be interpreted alongside full clinical context, imaging, and histopathology. No single marker defines aggressiveness. This test provides a comprehensive immunophenotypic map to guide precision therapy, but clinical correlation is imperative.”

Advisory: Pre-Procedure Medication Considerations

Do not discontinue prescribed medications without consulting your physician. Some medications (e.g., somatostatin analogs, proton pump inhibitors) may affect neuroendocrine marker expression. Always inform your doctor about all current treatments before biopsy.

Exclusion Criteria & Emergency Red Flags

Patients with severe coagulopathy or bleeding diathesis require pre-procedural clearance.
Tissue samples must be adequate; necrotic or extensively crushed biopsies may yield inconclusive results.
In case of sudden severe pain, hemodynamic instability, or signs of carcinoid crisis post-biopsy, seek emergency medical attention immediately.

Patient FAQ & Clinical Guidance

1. What is the Immunohistochemistry Neuroendocrine Tumor Panel?

This panel uses a set of antibodies (including chromogranin A, synaptophysin, CD56, Ki-67, and hormonal markers) to characterize the immunophenotype of neuroendocrine tumors from FFPE tissue, aiding in diagnosis, grading, and therapeutic target identification.

2. What type of sample is required and how should it be submitted?

Formalin-fixed paraffin-embedded (FFPE) tissue blocks or unstained slides are required. Previously stored blocks are acceptable if fixation was adequate. Submit with a copy of the histopathology report, biopsy site, and clinical history via secure medical courier. Home phlebotomy is not available for this archival specimen.

3. What is the turnaround time?

Standard turnaround is 5 days for simple cases and up to 7 days for complex panels, from receipt of adequate tissue. Expedited processing may be arranged on request.

4. Does insurance cover this test and how can I verify coverage?

We offer direct billing assistance. Contact our team via WhatsApp at +971 54 548 8731 with your insurance details for pre-approval verification. Most major UAE insurers cover this essential diagnostic panel.

5. How does this panel guide treatment decisions?

By providing a detailed immunophenotypic map including proliferative index (Ki-67) and specific differentiation markers, it enables accurate tumor grading and identifies potential targets for somatostatin receptor-based therapy or other precision treatments.

UAE Regulatory & Data Privacy Adherence

This diagnostic service operates under the oversight of the Dubai Health Authority (DHA) Facility License No. 1143. All patient data, clinical records, and test results are processed in strict compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient confidentiality, informed consent (consistent with Federal Decree-Law No. 4 of 2016 on Medical Liability), and secure data management are integral to our workflow.

Clinical & Logistical Metadata

Test Name	Immunohistochemistry Neuroendocrine Tumor Panel
Price (AED)	1,000 AED
Turnaround Time	5–7 working days from tissue receipt
Sample Type / Matrix	Formalin-Fixed Paraffin-Embedded (FFPE) Tissue Block / Unstained Slides
Methodology Used	Automated IHC (BenchMark Ultra) with digital quantification and board-certified pathologist interpretation
ICD-10-CM Code	C7A.00 (Malignant carcinoid tumor, unspecified site)
LOINC Code	55153-3 (Immunohistochemistry (IHC) panel - Tissue)
DHA Facility License & Address	Licence No: 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE